Peer Review Program for Mental Health Medication.

This program was established to address the concerns that an increasing number of children are being prescribed antipsychotics and there is a lack of laboratory monitoring of those children.  The goal of the program is to ensure that children and adolescents receive optimal treatment in conjunction with appropriate non-pharmacologic measures in the safest manner possible.
This program began in October 2011 and initially addressed the use of antipsychotics in Medicaid patients under five years of age.  In July 2012, it expanded to encompass children under 10 years of age. In 2013, the program began to include all children under the age of 18 years.  
Below is the planned expansion chart of the program.  If you are requesting a Tier II or Non-Preferred antipsychotic drug for any child within the 10 to 17 year age range, the Tier II and Non-Preferred prior authorization will ONLY be approved for a LIMITED TIME.  The child will then need to be converted into the peer review program.  Based on the schedule below, you will be contacted by someone from the Peer Review Program.
Thank you in advance for your cooperation during this transition phase.
Patient Age (Years)
Time Period for Prescriber to Contact Peer Review Program
Date Prescription Will Start Denying at the Pharmacy

Early July to Early September
September 16, 2013

Early August to Mid October
October 22, 2013
12 to 13

Early September to Mid November
November 19, 2013
14 to 15

Late September to Early December
December 16, 2013
16 to 17

Mid October to Early January
January 17, 2014
The program works in partnership with the Mental Hygiene Administration (MHA) and the University of Maryland (UMD) School of Pharmacy and Division of Child and Adolescent Psychiatry. 
The MMPP and the MHA hosted a webinar to discuss the PRP and answer questions regarding this program on September 15, 2011. 
To view the power point used during the above mentioned webinar,